Navidence, a tech company focused on making health data clearer and easier to use, has announced it has closed its Series Seed funding round. The round was led by Grand Ventures and Nina Capital. The company aims to help researchers better understand and use real-world data (RWD) for clinical studies. With this new investment, Navidence plans to expand its tools that streamline the way health data is defined and applied in research.

Transforming How Real-World Data Is Used in Healthcare

Real-world data is increasingly important in developing and evaluating new therapies. However, researchers often find it hard to work with because data definitions are inconsistent or fragmented. Navidence’s platform tackles this problem by creating standard, human- and machine-readable definitions called Computable Operational Definitions (CODefs). These definitions help connect clinical care data with research needs, making data more reliable and easier to interpret.

The company’s approach combines advanced AI technology with curated libraries of these definitions and expert support. This makes it easier for research teams to design studies and select the right data for their specific questions. By providing clear, standardized definitions, Navidence aims to reduce delays and errors in clinical research, ultimately speeding up the development of new treatments.

Supporting Researchers and Regulatory Compliance

As the use of real-world data grows, so does the need for trust and clarity in how data is defined and used. Regulatory agencies demand high standards for data quality and consistency. Navidence’s platform helps meet these demands by offering a framework that ensures data is standardized and trustworthy. This makes it easier for pharmaceutical companies and researchers to meet regulatory requirements and gain approval for new therapies.

James Hill from Grand Ventures emphasizes that Navidence is building essential infrastructure for the industry. Its combination of software and domain expertise helps translate complex healthcare data into standardized, reusable definitions. This foundation could make Navidence a key player in RWD-driven research, supporting better decision-making and faster drug development.

Nina Capital’s Sebastian Anastassiou adds that Navidence acts like a “Rosetta Stone” for health data. It bridges the gap between clinical care and research by transforming diverse health information into a standardized, computable format. This innovation addresses a fundamental bottleneck in healthcare data, helping researchers and companies make better use of real-world evidence.

Overall, Navidence’s new funding marks a significant step towards more transparent, efficient, and trustworthy use of health data in clinical research. Its technology aims to reduce manual work, improve data quality, and support faster, more accurate decision-making in the development of new medicines and therapies.

Inspired by

• https://ai-techpark.com/navidence-raises-funding-to-bring-clarity-to-rwd-driven-clinical-research/